Pharma BD Deal Intelligence
A worldwide licensing win: Eli Lilly paid Incyte $90 million upfront for INCB28050, an oral JAK1/JAK2 inhibitor, plus up to $665 million in milestones and royalties. The molecule became Olumiant, approved for rheumatoid arthritis, atopic dermatitis, alopecia areata, and COVID-19 hospitalization.
Eli Lilly obtained an exclusive worldwide license and collaboration agreement with Incyte for INCB28050 (baricitinib), an oral JAK1/JAK2 inhibitor, and certain follow-on compounds for inflammatory and autoimmune diseases. Incyte received $90 million upfront and was eligible for up to $665 million in development, regulatory, and commercialization milestones plus tiered double-digit royalties on global sales. Baricitinib was subsequently approved as Olumiant for rheumatoid arthritis (2017 EU, 2018 US), atopic dermatitis, alopecia areata, and COVID-19 hospitalization. Incyte retained option to co-promote in the US.
16.5M US cases/yr · $5.0B US Atopic Dermatitis Market (2009) · 7.3% US Adult AD Prevalence
Atopic dermatitis is a chronic inflammatory skin disease affecting up to 16.5 million US adults. In 2009, treatment options were limited to topical corticosteroids and immunosuppressants. No targeted systemic therapies were approved, creating massive unmet need.
In 2009, there were no approved targeted systemic therapies for AD. Dupilumab (Dupixent) was in early development and would be approved in 2017. Baricitinib was approved for AD in Europe (2020). US JAK AD approvals included upadacitinib (2022) and abrocitinib (2022).
1.3M US cases/yr · $8.5B US RA Therapeutics Market (2009)
Rheumatoid arthritis affects ~1.3M Americans with significant unmet need despite TNF inhibitor availability. The Lilly-Incyte collaboration targeted JAK1/JAK2 with baricitinib (INCB28050), representing a new oral mechanism for RA. JAK inhibitors promised the efficacy of biologics in a pill form.
In 2009, RA treatment was dominated by TNF inhibitors (Enbrel, Humira, Remicade). Pfizer's tofacitinib was furthest ahead in JAK development. Baricitinib would eventually receive FDA approval in 2018 for RA and expanded to COVID-19 (EUA 2020) and alopecia areata (2022).
1.3M US cases/yr · $15.0B US Autoimmune Therapeutics Market (2009)
Autoimmune and inflammatory diseases amenable to JAK1/JAK2 inhibition share dependence on cytokine receptors that signal via Janus kinases, including IL-6, IFN-gamma, GM-CSF, and common gamma-chain cytokines. Rheumatoid arthritis affects ~1.3M US adults with progressive synovial destruction; atopic dermatitis affects ~7% of US adults with Th2-driven barrier dysfunction; alopecia areata affects ~2% lifetime prevalence with T-cell attack on hair follicles. JAK inhibition blunts multiple downstream inflammatory pathways simultaneously.
Baricitinib (Olumiant, Lilly/Incyte) competes with tofacitinib (Xeljanz, Pfizer), upadacitinib (Rinvoq, AbbVie), and abrocitinib (Cibinqo, Pfizer) across RA, atopic dermatitis, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis. In alopecia areata the class includes ritlecitinib (Litfulo, Pfizer) and deuruxolitinib (Leqselvi, Sun Pharma). Topical ruxolitinib (Opzelura, Incyte) serves AD and vitiligo.
Incyte received $90M upfront for worldwide license on baricitinib (JAK1/JAK2) for autoimmune diseases.
Eli Lilly and Company closes licensing/option of Incyte Corporation for $900M, establishing strategic position and initiating integration.
FDA approved Olumiant for severe alopecia areata. Also approved for RA (2018) and COVID-19 (2022).
Olumiant approved for RA, alopecia areata, COVID-19, and atopic dermatitis (ex-US). Approved in 75+ countries.
Strategic Fit: 78/100 | Financial Return: 72/100 | Pipeline Outcome: 70/100 | Integration: 75/100 | Deal Difficulty: 45/100. Achieved Stated Rationale overall outcome.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Incyte Corporation (this deal) | 2009 | $755M | 69 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Hanmi Pharmaceutical Co. Ltd. | 2026 | $1.3B | 65 |
← Browse all deals · How we score deals
More: 2009 deals · Eli Lilly and Company deals · Dermatology deals